acrylonitrile has been researched along with B-Cell Chronic Lymphocytic Leukemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Best, OG; Crassini, K; Mulligan, SP; Stevenson, WS | 1 |
1 other study(ies) available for acrylonitrile and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
Topics: Acrylonitrile; Aniline Compounds; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Coculture Techniques; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-akt; Stromal Cells; Tumor Microenvironment; Vidarabine | 2015 |